LIBERTYVILLE, Ill., June 18 /PRNewswire-USNewswire/ -- Families of Spinal Muscular Atrophy has just released details of the latest developments for the Families of SMA funded therapeutic pipeline. Families of SMA is currently funding three distinct drug discovery programs: 1) Quinazolines to boost gene expression; 2) Tetracyclines at Paratek Pharmaceuticals to correct gene splicing; and 3) Motor neuron replacement program at California Stem Cell and UCI.

Paratek Pharmaceuticals, a developer of therapeutics for treating bacterial infections, has announced positive Phase II data of the company's lead antibiotic, PTK 0796, a first-in-class aminomethylcycline.